| 초록 |
Computed tomography (CT) is one of the diagnostic tools but it is difficult to diagnose disease in soft tissues. So, CT contrasts are important to improve CT contrast image in soft tissues. Bile duct imaging is typically performed endoscopic retrograde cholangiopancreatography (ERCP). But ERCP is invasive diagnosis method. Solve this problem, we develop I.V. injectable liver targeted CT contrast agent (ILTC). ILTC is composed with iodine-based molecule, targeting molecule, solubility increasing molecules. Targeting molecule can bind receptor in liver. In vitro, we have confirmed specific binding and uptake in liver cells (receptor positive) and non-liver cells (receptor negative). In vivo, we have confirmed the biodistribution of body and confirmed the content of iodine in bile juice compared with the commercially available contrast agent (CACA). We have confirmed contrast effect in the bile duct in CT image. We have confirmed elimination of ILTC by detecting ILTC in urine and feces. |
